Shares of Biodesix, Inc. BDSX, a lung disease-focused diagnostics company, skyrocketed in after-hours trading on Monday.
What Happened: Biodesix's rally was in response to a series of filings by the company disclosing stock purchases by its chairman and a couple of its directors.
John Patience, serving as the director of the board, bought 279,329 shares in the company at $1.79 per share, while Matthew Strobeck and Jack Schuler, both serving as directors, picked up 558,659 and 2.79 million shares, respectively. The per-share pricing of the transactions was above the high-end of Monday's trading range.
Following the recent transactions, Schuler's stake in Biodesix is at 11.268 million or 29.3%.
An announcement from Biodesix ahead of the market open regarding the private placement of 6.51 million shares to raise $11.7 million in net proceeds and an amendment to its term loan agreement to relax the covenant terms sent the stock down by over 5% in regular trading on Monday.
This private placement included the shares bought by the three company insiders.
Related Link: The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Why It's Important: Biodesix went public in October 2020. After closing the debut session at $12.81 and seeing some upward bounce until late January 2021, the stock has been tracing a broader downward trajectory.
The latest financial results reported in mid-March showed a 73% plunge in revenue, as COVID-19 diagnostics revenue tapered off from $21.43 million a year ago to merely $425,000. The company's cash balance nearly halved to $32.71 million.
The fund infusion, apart from the psychological effect of lifting the stock price, is important for Biodesix to survive as a going concern until lung diagnostics revenues can grow strongly.
Author's Take: The fund infusion, apart from the psychological effect of lifting the stock price, is important for Biodesix to survive as a going concern until lung diagnostics revenues can grow strongly.
Price Action: Biodesix shares jumped 81.13% to $2.88 in Monday's after-hours trading.
Related Link: Merck Continues to See Executive Exodus; Here's A Look At All Recent Departures
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
